MedTrace Logo

First in Human Study of CT-1500 in Healthy Participants

NCT05070702 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-07-15

No results posted yet for this study

Summary

This study is a single center, randomized, placebo-controlled, double-blind study of CT-1500 in healthy volunteers. The study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses and multiple ascending doses of orally administered CT-1500 compared to placebo.

Conditions

  • Healthy

Interventions

DRUG

CT-1500

Hard Capsule

DRUG

Placebo

Hard Capsule

Sponsors & Collaborators

  • Neuroscience Trials Australia

    collaborator OTHER

  • Circadian Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Philip Ryan, Dr · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-08
Primary Completion
2022-07-07
Completion
2022-07-07

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05070702 on ClinicalTrials.gov